Liver

SAN DIEGO — Once-daily FXR314 was well-tolerated and safely improved liver fat content and biochemical markers over 16 weeks in patients with metabolic dysfunction-associated steatohepatitis, according to research at The Liver Meeting.

Hepatic adverse events with bimekizumab were low and consistent through 2 years of treatment among patients with moderate to severe psoriasis, according to a study.

Non-alcoholic fatty liver disease is an independent risk factor for osteoarthritis, according to data published in Arthritis Research & Therapy.

Topline findings from the phase 2a DUET trial showed that Tern Pharmaceuticals’ oral thyroid hormone receptor-beta agonist achieved significant reductions in liver fat content among patients with nonalcoholic steatohepatitis.

A recent systematic review and meta-analysis revealed that moderate to high doses of cannabidiol were associated with liver enzyme elevation and drug-induced liver injury, meeting the criteria of common adverse drug events.

Isolated hepatic perfusion conferred superior overall response rates and longer PFS than best alternative care among previously untreated patients with isolated liver metastases from primary uveal melanoma according to study results.

An FDA mandate limiting acetaminophen in medications combining acetaminophen and opioids was associated with a reduction in serious liver injuries, a recent study in JAMA found.

Non-heavy alcohol consumption was associated with fibrosis and at-risk nonalcoholic steatohepatitis, prompting researchers to suggest that current fatty liver disease categorization as alcoholic or nonalcoholic may be “misleading.”

Robotic liver dissection appeared safe and effective compared with open liver resection among patients with hepatocellular carcinoma, according to study results published in JAMA Surgery.

WASHINGTON — Efruxifermin improved liver histology, liver fat content and noninvasive markers of disease in patients with stage 2 or 3 fibrosis related to nonalcoholic steatohepatitis, according to late-breaking data at The Liver Meeting.